{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T02:07:49Z","timestamp":1788746869129,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001043","name":"Cass Foundation","doi-asserted-by":"publisher","award":["10453"],"award-info":[{"award-number":["10453"]}],"id":[{"id":"10.13039\/501100001043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2012523"],"award-info":[{"award-number":["2012523"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16390-8","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:23:18Z","timestamp":1782271398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Podocalyxin may be down-regulated by progesterone in high grade serous ovarian cancer spheroids to increase responsiveness to carboplatin and NK cells"],"prefix":"10.1186","volume":"26","author":[{"given":"Ngoc","family":"Le Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie M","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maree","family":"Bilandzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiying","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"3","key":"16390_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"16390_CR2","doi-asserted-by":"crossref","unstructured":"Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian cancer immunotherapy and personalized medicine. Int J Mol Sci. 2021;22(12):6532.","DOI":"10.3390\/ijms22126532"},{"key":"16390_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bios.2019.03.041","volume":"135","author":"B Franier","year":"2019","unstructured":"Franier B, Thompson M. Early stage detection and screening of ovarian cancer: A research opportunity and significant challenge for biosensor technology. Biosens Bioelectron. 2019;135:71\u201381.","journal-title":"Biosens Bioelectron"},{"issue":"16","key":"16390_CR4","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1002\/cam4.2560","volume":"8","author":"A Chandra","year":"2019","unstructured":"Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 2019;8(16):7018\u201331.","journal-title":"Cancer Med"},{"issue":"11","key":"16390_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, B\u00f6hm S, Ahmed AA, Aspuria PJ, Bast R, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668\u201379.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"16390_CR6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053\u201364.","journal-title":"Am J Pathol"},{"issue":"1","key":"16390_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","volume":"113","author":"K Shield","year":"2009","unstructured":"Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol. 2009;113(1):143\u20138.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"16390_CR8","first-page":"515","volume":"14","author":"S Makhija","year":"1999","unstructured":"Makhija S, Taylor DD, Gibb RK, Gercel-Taylor C. Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. Int J Oncol. 1999;14(3):515\u201321.","journal-title":"Int J Oncol"},{"issue":"5","key":"16390_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4149\/neo_2013_071","volume":"60","author":"H Huang","year":"2013","unstructured":"Huang H, Li YJ, Lan CY, Huang QD, Feng YL, Huang YW, et al. Clinical significance of ascites in epithelial ovarian cancer. Neoplasma. 2013;60(5):546\u201352.","journal-title":"Neoplasma"},{"issue":"11","key":"16390_CR10","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41577-018-0077-4","volume":"18","author":"L Chiossone","year":"2018","unstructured":"Chiossone L, Dumas PY, Vienne M, Vivier E. Author Correction: Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18(11):726.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"16390_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ygyno.2020.03.020","volume":"157","author":"JS Hoogstad-van Evert","year":"2020","unstructured":"Hoogstad-van Evert JS, Bekkers R, Ottevanger N, Jansen JH, Massuger L, Dolstra H. Harnessing natural killer cells for the treatment of ovarian cancer. Gynecol Oncol. 2020;157(3):810\u20136.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"16390_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203\u201313.","journal-title":"N Engl J Med"},{"issue":"2","key":"16390_CR13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","volume":"20","author":"JR Webb","year":"2014","unstructured":"Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014;20(2):434\u201344.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"16390_CR14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jcyt.2013.05.022","volume":"15","author":"MA Geller","year":"2013","unstructured":"Geller MA, Knorr DA, Hermanson DA, Pribyl L, Bendzick L, McCullar V, et al. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy. 2013;15(10):1297\u2013306.","journal-title":"Cytotherapy"},{"issue":"1","key":"16390_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","volume":"21","author":"L Tong","year":"2022","unstructured":"Tong L, Jimenez-Cortegana C, Tay AHM, Wickstrom S, Galluzzi L, Lundqvist A. NK cells and solid tumors: therapeutic potential and persisting obstacles. Mol Cancer. 2022;21(1):206.","journal-title":"Mol Cancer"},{"key":"16390_CR16","doi-asserted-by":"publisher","first-page":"101709","DOI":"10.1016\/j.smim.2022.101709","volume":"66","author":"N Lopes","year":"2023","unstructured":"Lopes N, Vivier E, Narni-Mancinelli E. Natural killer cells and type 1 innate lymphoid cells in cancer. Semin Immunol. 2023;66:101709.","journal-title":"Semin Immunol"},{"issue":"1","key":"16390_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ygyno.2006.02.025","volume":"103","author":"M Hinkula","year":"2006","unstructured":"Hinkula M, Pukkala E, Kyyronen P, Kauppila A. Incidence of ovarian cancer of grand multiparous women\u2013a population-based study in Finland. Gynecol Oncol. 2006;103(1):207\u201311.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"16390_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/joim.12747","volume":"283","author":"R Troisi","year":"2018","unstructured":"Troisi R, Bjorge T, Gissler M, Grotmol T, Kitahara CM, Myrtveit Saether SM, et al. The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. J Intern Med. 2018;283(5):430\u201345.","journal-title":"J Intern Med"},{"issue":"2","key":"16390_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ijc.31063","volume":"142","author":"K Gaitskell","year":"2018","unstructured":"Gaitskell K, Green J, Pirie K, Barnes I, Hermon C, Reeves GK, et al. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. Int J Cancer. 2018;142(2):281\u20139.","journal-title":"Int J Cancer"},{"issue":"8","key":"16390_CR20","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.15419\/bmrat.v4i08.228","volume":"4","author":"M Mohammadian","year":"2017","unstructured":"Mohammadian M, Ghafari M, Khosravi B, Salehiniya H, Aryaie M, Bakeshei FA, et al. Variations in the Incidence and Mortality of Ovarian Cancer and Their Relationship with the Human Development Index in European Countries in 2012. Biomed Res Ther. 2017;4(8):1541\u201357.","journal-title":"Biomed Res Ther"},{"issue":"10","key":"16390_CR21","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/sj.bjc.6603457","volume":"95","author":"JK Chan","year":"2006","unstructured":"Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95(10):1314\u201320.","journal-title":"Br J Cancer"},{"issue":"4","key":"16390_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/cmt.4.4.267.272","volume":"4","author":"MR Soules","year":"2001","unstructured":"Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric. 2001;4(4):267\u201372.","journal-title":"Climacteric"},{"issue":"25","key":"16390_CR23","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","volume":"142","author":"SR El Khoudary","year":"2020","unstructured":"El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506\u201332.","journal-title":"Circulation"},{"issue":"2","key":"16390_CR24","first-page":"69","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"16390_CR25","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00404-020-05458-w","volume":"301","author":"D Huber","year":"2020","unstructured":"Huber D, Seitz S, Kast K, Emons G, Ortmann O. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet. 2020;301(4):875\u201384.","journal-title":"Arch Gynecol Obstet"},{"issue":"9609","key":"16390_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","volume":"371","author":"C Beral","year":"2008","unstructured":"Collaborative Group on Epidemiological Studies of Ovarian, Beral C, Doll V, Hermon R, Peto C, Reeves R. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303\u201314.","journal-title":"Lancet"},{"issue":"1","key":"16390_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1158\/1055-9965.EPI-19-0734","volume":"29","author":"T Huang","year":"2020","unstructured":"Huang T, Townsend MK, Wentzensen N, Trabert B, White E, Arslan AA, et al. Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3). Cancer Epidemiol Biomarkers Prev. 2020;29(1):200\u20137.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"16390_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/1055-9965.98.14.1","volume":"14","author":"A Lukanova","year":"2005","unstructured":"Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005;14(1):98\u2013107.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"16390_CR29","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1054\/bjoc.2000.1463","volume":"83","author":"J Akahira","year":"2000","unstructured":"Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer. 2000;83(11):1488\u201394.","journal-title":"Br J Cancer"},{"issue":"10","key":"16390_CR30","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3109\/09513590.2010.538100","volume":"27","author":"H Nguyen","year":"2011","unstructured":"Nguyen H, Syed V. Progesterone inhibits growth and induces apoptosis in cancer cells through modulation of reactive oxygen species. Gynecol Endocrinol. 2011;27(10):830\u20136.","journal-title":"Gynecol Endocrinol"},{"issue":"50","key":"16390_CR31","doi-asserted-by":"publisher","first-page":"31993","DOI":"10.1073\/pnas.2013595117","volume":"117","author":"O Kim","year":"2020","unstructured":"Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, et al. Targeting progesterone signaling prevents metastatic ovarian cancer. Proc Natl Acad Sci U S A. 2020;117(50):31993\u20132004.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"16390_CR32","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1681\/ASN.2008070782","volume":"20","author":"JS Nielsen","year":"2009","unstructured":"Nielsen JS, McNagny KM. The role of podocalyxin in health and disease. J Am Soc Nephrol. 2009;20(8):1669\u201376.","journal-title":"J Am Soc Nephrol"},{"key":"16390_CR33","doi-asserted-by":"crossref","unstructured":"Le Tran N, Wang Y, Nie G. Podocalyxin in normal tissue and epithelial cancer. Cancers (Basel). 2021;13(12):2863.","DOI":"10.3390\/cancers13122863"},{"issue":"15","key":"16390_CR34","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1158\/0008-5472.CAN-04-0240","volume":"64","author":"A Somasiri","year":"2004","unstructured":"Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, et al. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res. 2004;64(15):5068\u201373.","journal-title":"Cancer Res"},{"issue":"3","key":"16390_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10585-011-9446-0","volume":"29","author":"JA Cipollone","year":"2012","unstructured":"Cipollone JA, Graves ML, Kobel M, Kalloger SE, Poon T, Gilks CB, et al. The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. Clin Exp Metastasis. 2012;29(3):239\u201352.","journal-title":"Clin Exp Metastasis"},{"key":"16390_CR36","doi-asserted-by":"crossref","unstructured":"Le Tran N, Wang Y, Bilandzic M, Stephens A, Nie GY. Podocalyxin promotes the formation of compact and chemoresistant cancer spheroids in high grade serous carcinoma. Sci Rep-Uk. 2024;14(1):7539.","DOI":"10.1038\/s41598-024-57053-7"},{"issue":"1","key":"16390_CR37","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1186\/s12885-025-15108-6","volume":"25","author":"N Le Tran","year":"2025","unstructured":"Le Tran N, Wang Y, Quinn KM, Bilandzic M, Stephens A, Nie G. Podocalyxin protects high grade serous ovarian cancer spheroids from NK cell infiltration and spheroid destruction. BMC Cancer. 2025;25(1):1674.","journal-title":"BMC Cancer"},{"issue":"5","key":"16390_CR38","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/humrep\/deab032","volume":"36","author":"SG Paule","year":"2021","unstructured":"Paule SG, Heng S, Samarajeewa N, Li Y, Mansilla M, Webb AI, et al. Podocalyxin is a key negative regulator of human endometrial epithelial receptivity for embryo implantation. Hum Reprod. 2021;36(5):1353\u201366.","journal-title":"Hum Reprod"},{"key":"16390_CR39","doi-asserted-by":"crossref","unstructured":"Shekibi M, Heng S, Wang Y, Samarajeewa N, Rombauts L, Nie G. Progesterone suppresses podocalyxin partly by up-regulating miR-145 and miR-199 in human endometrial epithelial cells to enhance receptivity in in vitro models. Mol Hum Reprod. 2022;28(11):gaac034.","DOI":"10.1093\/molehr\/gaac034"},{"key":"16390_CR40","doi-asserted-by":"crossref","unstructured":"Paule SG, Heng S, Samarajeewa N, Li Y, Mansilla M, Webb AI et al. Podocalyxin is a key negative regulator of human endometrial epithelial receptivity for embryo implantation. Hum Reprod. 2021.","DOI":"10.1093\/humrep\/deab032"},{"issue":"4","key":"16390_CR41","doi-asserted-by":"publisher","first-page":"20200137","DOI":"10.1515\/pp-2020-0137","volume":"5","author":"MS Mikkelsen","year":"2020","unstructured":"Mikkelsen MS, Blaakaer J, Petersen LK, Schleiss LG, Iversen LH. Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer. Pleura Peritoneum. 2020;5(4):20200137.","journal-title":"Pleura Peritoneum"},{"issue":"4","key":"16390_CR42","doi-asserted-by":"publisher","first-page":"e0123208","DOI":"10.1371\/journal.pone.0123208","volume":"10","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Zhang L, Pan H, Wang B, Yan F, Fang X, et al. Bmi1 essentially mediates podocalyxin-enhanced Cisplatin chemoresistance in oral tongue squamous cell carcinoma. PLoS ONE. 2015;10(4):e0123208.","journal-title":"PLoS ONE"},{"issue":"3","key":"16390_CR43","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.3892\/mmr.2015.3859","volume":"12","author":"Z Huang","year":"2015","unstructured":"Huang Z, Huang Y, He H, Ni J. Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling. Mol Med Rep. 2015;12(3):3916\u201322.","journal-title":"Mol Med Rep"},{"issue":"1","key":"16390_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/stem.2230","volume":"34","author":"DL Hermanson","year":"2016","unstructured":"Hermanson DL, Bendzick L, Pribyl L, McCullar V, Vogel RI, Miller JS, et al. Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer. Stem Cells. 2016;34(1):93\u2013101.","journal-title":"Stem Cells"},{"issue":"3","key":"16390_CR45","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1371\/journal.pone.0000326","volume":"2","author":"R Bhat","year":"2007","unstructured":"Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells\u2013enhancement by therapeutic antibodies. PLoS ONE. 2007;2(3):e326.","journal-title":"PLoS ONE"},{"issue":"11\u201312","key":"16390_CR46","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3727\/096368911X580536","volume":"20","author":"M Cheng","year":"2011","unstructured":"Cheng M, Ma J, Chen Y, Zhang J, Zhao W, Zhang J, et al. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line. Cell Transpl. 2011;20(11\u201312):1731\u201346.","journal-title":"Cell Transpl"},{"key":"16390_CR47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12885-015-1321-y","volume":"15","author":"A Giannattasio","year":"2015","unstructured":"Giannattasio A, Weil S, Kloess S, Ansari N, Stelzer EH, Cerwenka A, et al. Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids. BMC Cancer. 2015;15:351.","journal-title":"BMC Cancer"},{"issue":"1","key":"16390_CR48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-019-0553-9","volume":"7","author":"T Courau","year":"2019","unstructured":"Courau T, Bonnereau J, Chicoteau J, Bottois H, Remark R, Assante Miranda L, et al. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA\/B and NKG2A targeting for cancer treatment. J Immunother Cancer. 2019;7(1):74.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"16390_CR49","doi-asserted-by":"publisher","first-page":"e1395123","DOI":"10.1080\/2162402X.2017.1395123","volume":"7","author":"PM Lanuza","year":"2018","unstructured":"Lanuza PM, Vigueras A, Olivan S, Prats AC, Costas S, Llamazares G, et al. Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression. Oncoimmunology. 2018;7(4):e1395123.","journal-title":"Oncoimmunology"},{"key":"16390_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers13194896","volume":"13","author":"T Morimoto","year":"2021","unstructured":"Morimoto T, Nakazawa T, Matsuda R, Nishimura F, Nakamura M, Yamada S, et al. Evaluation of Comprehensive Gene Expression and NK Cell-Mediated Killing in Glioblastoma Cell Line-Derived Spheroids. Cancers (Basel). 2021;13:19.","journal-title":"Cancers (Basel)"},{"key":"16390_CR51","doi-asserted-by":"crossref","unstructured":"Hoogstad-van Evert JS, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R, et al. Umbilical cord blood CD34 progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD\/SCID\/IL2Rg mice. Oncoimmunology. 2017;6(8):e1320630.","DOI":"10.1080\/2162402X.2017.1320630"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16390-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16390-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16390-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:27:26Z","timestamp":1788744446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16390-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16390"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16390-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Primary HGSC cells were acquired from ascites fluid of patients admitted to Eastern Health hospitals in Melbourne, Australia; ethics approval was obtained from Monash University Human Research Ethics Committee (#06032\u00a0C). Human NK cells were isolated from PBMC\u2019s derived from whole blood of healthy patients provided by the Australian Red Cross with ethics approval by RMIT College of Human Ethics Advisory Network (#28056). All work was conducted according to the Declaration of Helsinki Principles and the Australian National Health and Medical Research Council (NHMRC) Code of Practice. Signed informed consent was obtained from all donors before the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1066"}}